FDA Will Not Be “Health SEC,” Chief Counsel Troy Tells Investors
This article was originally published in The Gray Sheet
Executive Summary
FDA and the Securities & Exchange Commission are making progress on formalizing communications about potentially misleading disclosures to investors, FDA Chief Counsel Dan Troy told attendees of a Schwab Washington Research Group conference May 15
You may also be interested in...
CDRH More Reliant On SEC, FTC For Ad/Promotion Vigilance Under Policy Shift
The Center for Devices & Radiological Health increasingly is looking to other federal agencies to help regulate medical device advertising and promotion as it scales back its own claim enforcement activities
Chinese Firms Up Their Game In Novel Flu Antiviral Development
Joincare Pharmaceutical and partner TaiGen Biotechnology tout preliminary Phase III results in uncomplicated acute influenza for TG-1000, a homegrown follower of Shionogi/Roche’s oral antiviral Xofluza. Novel antivirals for flu were hotly pursued by Chinese developers throughout 2023.
Quotable: Words Of Wisdom From Our Recent APAC Coverage
Scrip's APAC team selects notable quotes from recent interviews, conferences and other coverage to highlight the views of senior executives and officials on the major topics facing the biopharma sector in the region.